Literature DB >> 9317126

Regulation of B lymphocyte development and activation by the CD19/CD21/CD81/Leu 13 complex requires the cytoplasmic domain of CD19.

S Sato1, A S Miller, M C Howard, T F Tedder.   

Abstract

B lymphocyte development and function are regulated in part by the CD19 cell surface receptor complex, which is composed of at least four proteins; CD19, CD21 (CR2, complement receptor 2), CD81, and Leu 13. Because this complex has eight membrane-spanning domains and six cytoplasmic regions, determining the molecular basis for its function and signal transduction activities has not been straightforward. In this study, the contribution of the CD19 cytoplasmic domain to the in vivo function of the CD19/CD21/CD81/Leu 13 complex was assessed by generating CD19-deficient mice that expressed a transgene that encoded only the extracellular and transmembrane domains of CD19. Mice expressing this transgene were similar, if not identical, to CD19-deficient mice with abnormal B cell development, a lack of B-1 cells, increased surface IgM levels on B cells, modest mitogen responses, minimal serum Ig levels, and low humoral immune responses. The results of this study indicate that specific signals generated through the cytoplasmic domain of CD19 are essential for B lymphocyte development and function, and that CD19 is the dominant signaling component of the CD19 complex. Moreover, expression of the CD19 cytoplasmic domain is required for optimal signaling through the B cell Ag receptor complex.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  The cytoskeleton coordinates the early events of B-cell activation.

Authors:  Naomi E Harwood; Facundo D Batista
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

2.  Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments.

Authors:  Tsipi Shoham; Ranjani Rajapaksa; Chiung-Chi Kuo; Joseph Haimovich; Shoshana Levy
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

3.  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Authors:  Farrukh T Awan; Rosa Lapalombella; Rossana Trotta; Jonathan P Butchar; Bo Yu; Don M Benson; Julie M Roda; Carolyn Cheney; Xiaokui Mo; Amy Lehman; Jeffrey Jones; Joseph Flynn; David Jarjoura; John R Desjarlais; Susheela Tridandapani; Michael A Caligiuri; Natarajan Muthusamy; John C Byrd
Journal:  Blood       Date:  2009-12-02       Impact factor: 22.113

4.  Expression and Cellular Localization of IFITM1 in Normal and Injured Rat Spinal Cords.

Authors:  Ying Wang; Yu-Hong Lin; Yan Wu; Zong-Feng Yao; Jie Tang; Lin Shen; Rui Wang; Shu-Qin Ding; Jian-Guo Hu; He-Zuo Lü
Journal:  J Histochem Cytochem       Date:  2018-01-04       Impact factor: 2.479

5.  A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice.

Authors:  Jonathan C Poe; Veronique Minard-Colin; Evgueni I Kountikov; Karen M Haas; Thomas F Tedder
Journal:  J Immunol       Date:  2012-07-23       Impact factor: 5.422

6.  Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.

Authors:  Rita Kansal; Noah Richardson; Indira Neeli; Saleem Khawaja; Damian Chamberlain; Marium Ghani; Qurat-Ul-Ain Ghani; Louisa Balazs; Sarka Beranova-Giorgianni; Francesco Giorgianni; James N Kochenderfer; Tony Marion; Lorraine M Albritton; Marko Radic
Journal:  Sci Transl Med       Date:  2019-03-06       Impact factor: 17.956

7.  Complement serves as a switch between CD4+ T cell-independent and -dependent RBC antibody responses.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Satheesh Chonat; Andreas Wieland; Manjula Santhanakrishnan; Jingchun Liu; Cheryl L Maier; Ryan P Jajosky; Kathryn Girard-Pierce; Ashley Bennett; Patricia E Zerra; Nicole H Smith; Jeanne E Hendrickson; Sean R Stowell
Journal:  JCI Insight       Date:  2018-11-15

8.  Antibody-mediated immunosuppression can result from RBC antigen loss independent of Fcγ receptors in mice.

Authors:  Amanda Mener; Seema R Patel; Connie M Arthur; Sean R Stowell
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

9.  A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression.

Authors:  Felipe Vences-Catalán; Chiung-Chi Kuo; Yael Sagi; Homer Chen; Neta Kela-Madar; Menno C van Zelm; Jacques J M van Dongen; Shoshana Levy
Journal:  J Clin Immunol       Date:  2015-03-06       Impact factor: 8.317

Review 10.  Immune-mediated animal models of Tourette syndrome.

Authors:  Mady Hornig; W Ian Lipkin
Journal:  Neurosci Biobehav Rev       Date:  2013-01-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.